Our current study is the product of linking and expanding our finding that HDAC6 knockdown NSCLC cells exhibit the enhanced cisplatin sensitivity [21] and our 2014 study, which describes E3 ubiquitin ligase activity contained in HDAC6’s DAC1 domain [22]. This evidence concerns the gene HDAC6 and non-small cell lung carcinoma.